MedTrace Logo

Endothelial Glycocalyx Damage in Acute Kidney Injury

NCT05471583 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2022-07-25

No results posted yet for this study

Summary

Abstract Significance: Cardiac surgery-associated acute kidney injury (CSA-AKI) is common and has serious immediate and long-term sequelae. Better early prediction of those at highest risk and greater understanding of underlying pathological processes are needed to prevent or minimise damage.

Hypotheses

* Dynamic changes in systemic endothelial glycocalyx (Glx) and microcirculatory parameters during coronary artery bypass graft (CABG) surgery are predictive of CSA-AKI.
* Mechanisms for Glx degradation during CABG surgery are akin to those during sepsis Aims
* Investigate Glx and microcirculatory health throughout CABG surgery and recovery and their association with CSA-AKI.
* Explore association between inflammation and Glx degradation during CABG surgery.

Methodology

1. Prospective cohort study: serial sampling and microcirculatory perfusion imaging of 70 patients undergoing CABG surgery with evaluation of CSA-AKI predictors, including plasma Syndecan-1.
2. Examination of inflammation and cardiometabolic proteome and association with vascular changes
3. In vitro mechanistic assessment of Glx degradation and relative timing of organelle exocytosis in cultured endothelial cells in response to patient serum, targeting identified candidate mediators.

Impact: Enhancing CSA-AKI risk stratification with new mechanistic biomarkers will enable individualised management of at-risk patients, and pathophysiological insights will create possible therapeutic targets, thus reducing morbidity, mortality and cost of CSA-AKI.

Conditions

Interventions

OTHER

Main group

no intervention; observational only

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    collaborator OTHER

  • British Heart Foundation

    collaborator OTHER

  • King's College London

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05471583 on ClinicalTrials.gov